Gold for adults, sil­ver for in­fants: Pfiz­er's Pre­vnar 2.0 head­ed to FDA months af­ter Mer­ck­'s green light

Pfiz­er was first to the fin­ish line for the next-gen pneu­mo­coc­cal vac­cine in adults, but Mer­ck beat its ri­val with a jab for chil­dren in June.

Now, two months af­ter Mer­ck’s 15-va­lent Vaxneu­vance won the FDA stamp of ap­proval for kids, Pfiz­er is out with some late-stage da­ta on its 20-va­lent shot for in­fants.

Known as Pre­vnar 20 for adults, Pfiz­er’s 20vP­nC will head to the FDA by the end of this year for an ap­proval re­quest in in­fants, the Big Phar­ma said Fri­day morn­ing. Dis­cus­sions with the FDA will oc­cur first and more late-stage pe­di­atric tri­als are ex­pect­ed to read out soon, in­form­ing the reg­u­la­to­ry path­way in oth­er coun­tries and re­gions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.